Dare Bioscience, Inc. announced additional positive data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD). Dare intends to review the data with the FDA, including discussing the data from assessments as early as the 4- and 8-week mark after randomization where women randomized to Sildenafil Cream exhibited improvement. Dare may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website, SEC filings, press releases, public conference calls and webcasts.

Dare will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidate, clinical trials and other matters.